Social Media and Pharmacovigilance, FDA, AE and Patient Recruitment at DIA2012

DIA 2012 Collaborate to Innovate

48th Annual Meeting
June 24-28, 2012
Philadelphia, PA

Pennsylvania Convention Center

What questions are on your mind regarding Social Media? Feel free to post a comment on your concerns or successes below.-W

Title: The Impact of Social Media on Product Promotion and Pharmacovigilance

Social media creates challenges and opportunities for the promotion and safety of drugs and other medical products. FDA and industry are working to optimize truthful product information and ways to gather adverse event data utilizing this resource

Tracks: Advertising & Promotion|Regulatory Affairs|Medical Communications

Presentation(s) & Speaker(s):
FDA Perspective
Thomas W. Abrams, MBA,RPh, Director, Office of Prescription Drug Promotion, CDER
FDA

Panelist
Gerald J. Dal Pan, MD, Acting Director, Office of Surveillance and Epidemiology, CDER
FDA

Industry Perspective
Paul James Savidge, JD,MBA, Vice President and Associate General Counsel
Bristol-Myers Squibb Company

Elizabeth E. Garrard, PharmD,RPh, Chief Safety Officer
Drug Safety Alliance, Inc.

Title: AE Reporting in the Era of Web 2.0: The Challenges of Having a Two-Way Conversation

This session will focus on the specific types of social media currently being used by pharmaceutical companies with discussion on their successes and challenges. In addition, discussions on AE identification and collection while emphasizing the need for practices and guidance on the use of social media.

Tracks: Clinical Research|Medical Communications|Advertising & Promotion

Presentation(s) & Speaker(s): 

Embracing and Incorporating New Technology (eg. Social media, iPad) into a Modern Pharmacovigilance System
Gregory J. Fiore, MD, President
SSI Strategy

Safety and Social Media: Returning the Intention to Report: Adding the Human Factor Back to High Tech
Michael A. Ibara, PharmD, Head of Safety Innovation
Pfizer Inc

Title: Social Media: The Promise and Pitfalls for Patient Recruitment

Social media has huge potential as a new set of tools to drive patient recruitment. How do you use it and what happens when you do? In this symposium, we will offer both successes and lessons learned from trying social media as a recruitment strategy.
 

Tracks: Advertising & Promotion

Presentation(s) & Speaker(s):

 Is Social Media the New Technology for Helping Patients Find Clinical Trials?
Richard Mayewski, Global Trial Optimization Specialist
Merck & Co., Inc.

Finding the “ePatient” for Your Clinical Trial
Rodney William Butt, MBA,MSc,MT, Principal Consultant, Clinical Operations
Hamilton Medical Consultants Group, Canada

When Social Media Undermines Clinical Trial Performance
Elizabeth A Moench, President and Chief Executive Officer
MediciGlobal

Title: Communicating Drug Safety Information Using Social Media: FDA and Industry Perspectives
FDA relays the latest drug safety information through drug safety communications which are disseminated using social media tools. This session provides FDA and industry perspectives on the development, communication, dissemination, and impact of drug safety communications.

Tracks: Medical Communications|Clinical Safety/Pharmacovigilance|Regulatory Affairs

Presentation(s) & Speaker(s): 

Communicating Drug Safety Information: FDA Perspective
Catherine Yu Chew, PharmD, Acting Deputy Director, Division of Drug Information, CDER
FDA

Communicating Drug Safety Information :FDA Perspectives
Gregory Busse, PhD, Senior Writer/Editor, Team Lead for Drug Safety Communications, CDER
FDA

Communicating Drug Safety Information: Industry Perspective
Sue E. James, Vice President, Global Regulatory and Quality, Consumer Healthcare
GlaxoSmithKline

 
Title: Social Media 2.0: The Power of Online Rare Disease Communities to Connect and Engage ePatients
Relevant case studies will be presented to demonstrate how online patient communities and social media are revolutionizing how patients gain access to disease and treatment information.

Tracks: Advertising & Promotion|Clinical Research 

Presentation(s) & Speaker(s): 
RareConnect: A Global Social Network for Rare Disease Communities and Patients
Mary Dunkle, Vice President of Communications
National Organization For Rare Disorders (NORD)

The Power of Patient-driven Research and Rare Disease Online Communities: The SCAD Ladies and Beyond
Brian Loew, CEO
Inspire

Biopharma and Social Media: A Case Study
Eric Grinstead, Senior Vice President, Commercial Operations
Synageva Biopharma Corporation